The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher programme.   Otarmeni is an adeno-associated virus vector-based gene therapy indicated for the treatment of paediatric and adult patients with severe-to-profound and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!